Back
Emergent BioSolutions 10K Form
Sell
35
EBS
Emergent BioSolutions
Last Price:
2.54
Seasonality Move:
-0.41%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-12-11 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-08-09 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-05-10 | 10Q | EBS/Emergent BioSolutions Quarterly |
2022-11-09 | 10Q | EBS/Emergent BioSolutions Quarterly |
2022-08-02 | 10Q | EBS/Emergent BioSolutions Quarterly |
2022-04-29 | 10Q | EBS/Emergent BioSolutions Quarterly |
Receive EBS News And Ratings
See the #1 stock for the next 7 days that we like better than EBS
EBS Financial Statistics
Sales & Book Value
Annual Sales: | $1.02B |
---|---|
Cash Flow: | $20.7M |
Price / Cash Flow: | 0 |
Annual Sales: | $12.44 |
Price / Book: | 0.21 |
Profitability
EPS (TTM): | -14.76000 |
---|---|
Net Income (TTM): | $-757.2M |
Gross Margin: | $317.6M |
Return on Equity: | -77.37% |
Return on Assets: | -31.52% |
Emergent BioSolutions Earnings Forecast
Key Emergent BioSolutions Financial Ratios
- The Gross Profit Margin over the past 22 years for EBS is 31.05%.
- The Selling, General & Administrative Expenses for EBS have been equal to 36.01% of Gross Profit Margin.
- The Research & Development expenses have been 10.89% of Revenue.
- The Interest Expense is -11.56% of Operating Income.
- The Net Earning history of EBS is -74.34% of Total Revenues.
- Per Share Earnings over the last 23 years have been positive in 12 years.
Emergent BioSolutions Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Drug Manufacturers - Specialty & Generic |
Sector: | Healthcare |
Current Symbol: | EBS |
CUSIP: | 29089Q |
Website: | emergentbiosolutions.com |
Debt
Debt-to-Equity Ratio: | 1.32 |
---|---|
Current Ratio: | 1.04 |
Quick Ratio: | 0.46 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0.71 |
EBS Technical Analysis vs Fundamental Analysis
Sell
35
Emergent BioSolutions (EBS)
is a Sell
Is Emergent BioSolutions a Buy or a Sell?
-
Emergent BioSolutions stock is rated a Sell
The current Emergent BioSolutions [EBS] share price is $2.59. The Score for EBS is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.